MedTrace Logo

Pharmacokinetics and Safety/Tolerability Profile of CKD-379

NCT05452525 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-10-18

No results posted yet for this study

Summary

A study to compare the pharmacokinetics and safety/tolerability between CKD-379 tablet and D759, D745, D150 combination

Conditions

  • Type II Diabetes Mellitus

Interventions

DRUG

CKD-379 I

1 tablet administration under fed condition

DRUG

CKD-379 II

1 tablet administration under fed condition

DRUG

D759+D745+D150

3 tablet coadministration under fed condition

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Jaeseong Oh, M.D., Ph.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-26
Primary Completion
2022-08-27
Completion
2022-09-21

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05452525 on ClinicalTrials.gov